• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

    1/13/25 8:00:00 AM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALEC alert in real time by email

    Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration

    Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025

    Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved

    $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today highlighted recent progress and strategic priorities for 2025.

    "Alector remains steadfast in our mission to deliver transformative treatments for neurodegenerative diseases. As we begin 2025, we are focused on the significant milestones ahead," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "We look forward to the anticipated topline data readout for the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, expected by the fourth quarter of 2025. Latozinemab has been granted Orphan Drug, Breakthrough Therapy, and Fast Track designations, and the upcoming data readout will be an important milestone for our program. The Phase 2 PROGRESS-AD trial of AL101/GSK4527226 is also advancing well, with approximately 75% of participants enrolled, and we anticipate reaching full enrollment in mid-2025.

    In parallel, we continue to advance our preclinical and research pipeline with key programs, including ADP037-ABC, a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease; ADP050-ABC, a brain-penetrant GCase replacement therapy for Parkinson's disease and Lewy body dementia; as well as ADP063-ABC and ADP064-ABC, brain-penetrant, tau-blocking therapeutic candidates. These programs leverage our Alector Brain Carrier technology platform, which aims to enhance therapeutic delivery to the brain. This could potentially lead to efficacy at lower doses, more convenient subcutaneous delivery and expanded therapeutic windows, as well as lower treatment costs. Additionally, ADP056, our reelin modulator, is designed to block tau pathology and promote synaptic function in Alzheimer's disease. Collectively, our programs support our broad and diverse strategy for advancing investigational treatments for neurodegenerative diseases. With our strong cash position, we are well-poised to continue advancing our clinical and preclinical pipeline."

    Recent Progress and 2025 Strategic Priorities:

    Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) Being Developed in Collaboration with GSK

    Latozinemab

    • The pivotal, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 clinical trial of latozinemab targeting frontotemporal dementia with a granulin gene mutation (FTD-GRN) is ongoing. Topline data are anticipated by the fourth quarter of 2025.



      • Latozinemab is a novel investigational human monoclonal antibody (mAb) designed to increase progranulin (PGRN) levels in the brain by inhibiting sortilin. It was granted U.S. Food and Drug Administration Breakthrough Therapy Designation for FTD-GRN in early 2024, and the company believes it is the most advanced PGRN-elevating candidate in development for this condition.

      • Heterozygous loss-of-function mutations in the GRN gene cause FTD due to PGRN haploinsufficiency.1,2



    AL101/GSK4527226

    • PROGRESS-AD, a global, randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating AL101/GSK4527226 in early Alzheimer's disease (AD), has reached approximately 75% of its target enrollment of 282 participants. Alector and GSK plan to complete trial enrollment in mid-2025.



      • ​AL101/GSK4527226 is an investigational human mAb designed to block and downregulate the sortilin receptor to elevate the level of PGRN in the brain in a manner that is similar to investigational latozinemab but with different pharmacokinetic and pharmacodynamic properties, making it suitable for the potential treatment of more prevalent neurodegenerative diseases.



      • Modest reduction in the levels of PGRN due to GRN gene mutations has been shown to be associated with an increased risk of developing AD. Conversely, an elevation of PGRN has been shown to be protective in animal models of AD.3

    Preclinical and Research Pipeline

    • Alector continues to advance its preclinical and research pipeline by leveraging its expertise in neuroscience and selectively applying its proprietary blood-brain barrier technology platform, Alector Brain Carrier (ABC). This strategic approach positions the company to develop therapeutic candidates for a range of neurodegenerative diseases.



      • ADP037-ABC is a proprietary anti-amyloid beta (Aβ) antibody paired with the company's ABC for the treatment of AD. It is designed to remove brain amyloid plaques, with the potential to reduce the risk of amyloid-related imaging abnormalities (ARIA) and enable subcutaneous delivery. It targets a validated epitope specific to brain amyloid plaques, combined with an optimized antibody constant region to enhance phagocytosis of Aβ plaques. By leveraging ABC technology, ADP037-ABC aims to clear Aβ efficiently, thereby reducing plaque accumulation and slowing disease progression while minimizing ARIA.



      • ADP050-ABC is a GCase replacement therapy paired with the company's proprietary ABC for GBA gene mutation carriers with Parkinson's disease (PD) and Lewy body dementia. In these patients, mutations in the GBA gene lead to deficient GCase activity. ADP050-ABC uses Alector-engineered GCase, which has been designed to have a longer half-life and to break down glucocerebroside, a lipid that accumulates in neurons and contributes to neurodegeneration. This mechanism aims to reduce cellular dysfunction and slow disease progression.



      • ADP056 is a reelin modulator designed to block tau pathology and promote synaptic function in AD. Reelin, a large, secreted protein, regulates neuronal function and tau accumulation. Gain-of-function reelin variants protect against familial AD through a mechanism that appears to uncouple amyloid and tau pathology. ADP056 is designed to mimic and exceed these protective effects of the reelin mutation.



      • ADP063-ABC and ADP064-ABC are therapeutic candidates paired with ABC that target tau pathology in AD through distinct approaches. ADP063-ABC combines a proprietary anti-tau antibody with ABC and an optimized antibody constant region. It is designed to block the spread of tau aggregates and has the potential for subcutaneous delivery. ADP064-ABC uses an anti-tau siRNA, which aims to prevent the synthesis of the tau mRNA and protein. Both approaches seek to potentially slow cognitive decline in AD.

    • In December 2024, Alector and co-recipient University of Luxembourg were awarded a $1.7 million grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for collaborative research on GPNMB, a PD target. The research will be used by Alector to advance its ADP027-ABC program, which targets GPNMB for the potential treatment of PD.

    As of September 30, 2024, Alector had $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call.

    About Alector

    Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically-validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for INFRONT-3, expected milestones, expectations of our collaborations, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission ("SEC"), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.

    REFERENCES

    1. Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 Aug 24;442(7105):916-9.
    2. Cruts M, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006 Aug 24;442(7105):920-4.
    3. Minami SS, et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. Nat Med. 2014 Oct;20(10):1157-64.

    Alector Contacts:

    Alector

    Katie Hogan

    202-549-0557

    [email protected]

    Argot Partners (media)

    David Rosen

    (212) 600-1494

    [email protected]

    Argot Partners (investors)

    Laura Perry

    212-600-1902

    [email protected]



    Primary Logo

    Get the next $ALEC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALEC

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    More analyst ratings

    $ALEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      12/6/24 5:30:28 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/12/24 7:21:57 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/7/24 12:41:31 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York) Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page w

      5/6/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ALEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 31% to 66,666 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      5/2/25 6:00:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $26,547 worth of shares (18,091 units at $1.47), decreasing direct ownership by 5% to 312,560 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $59,176 worth of shares (40,330 units at $1.47), decreasing direct ownership by 2% to 2,466,744 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Financials

    Live finance-specific insights

    See more
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alector downgraded by Mizuho with a new price target

      Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously

      12/17/24 7:23:27 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Stifel with a new price target

      Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00

      12/16/24 6:41:43 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Neutral to Underperform and set a new price target of $1.00 from $9.00 previously

      12/4/24 7:19:54 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Alector Inc.

      DEFA14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:02:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALEC
    Leadership Updates

    Live Leadership Updates

    See more
    • Alector Reports First Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

      5/8/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

      3/29/22 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

      2/7/22 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care